Ribonucleic Acid (RNA) Markers Market, by Type (Prestained Markers, Unstained Markers and Specialty Markers), by Application (Nucleic Acid Applications and Proteomics Applications), by End User (Research Centers, Pharmaceutical and Biotechnology Companies

Ribonucleic Acid (RNA) Markers Market, by Type (Prestained Markers, Unstained Markers and Specialty Markers), by Application (Nucleic Acid Applications and Proteomics Applications), by End User (Research Centers, Pharmaceutical and Biotechnology Companies and Others (Academic Institutes, Forensic Laboratory and Others)) by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

A molecular marker (identified as genetic marker) is a fragment of DNA or RNA, which is associated with a certain location within the genome or RNA Pool. Molecular markers are used in molecular biology and biotechnology to identify a particular sequence of DNA or RNA in a pool of unknown nucleic acid sequence. RNA markers are used for the size estimation of single stranded RNA. For example, Promega Corporation, manufacturer of enzymes and other products for biotechnology and molecular biology is offering RNA markers and these markers are suitable for size estimation of single-stranded RNA from 0.28–6.58kb in glyoxal or formaldehyde-agarose gels. The RNA markers consist of a ladder of nine RNA transcripts that are synthesized in vitro from specific templates. The sizes are 281, 623, 955, 1,383, 1,908, 2,604, 3,638, 4,981 and 6,583 bases. The markers can be visualized by ethidium bromide staining.

Market Dynamics

Market players are indulged in expansion of manufacturing facilities, which is expected to drive the growth of the global ribonucleic acid (RNA) markers market, over the forecast period. For instance, on 20 January 2023, Moderna, Inc., an U.S. based pharmaceutical and biotechnology company, is planning to expand its manufacturing capacity in Canada, as part of a 10-year partnership with the Canadian government in order to strengthen the company’s pandemic response. Moreover, the company is also planning to expand its manufacturing facility in Australia, for the same reason as above. The company is also planning to expand its manufacturing facility in Kenya. The Australian facility is expected to produce up to 100 million mRNA vaccine doses annually, including for respiratory infections. The new facility in Kenya is expected to produce at least of 500 million vaccine doses per year.

Key features of the study:

• This report provides in-depth analysis of the global ribonucleic acid (RNA) markers market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global ribonucleic acid (RNA) markers market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies Key companies covered as a part of this study include Agilent Technologies, Inc., Oxford Gene Technology IP Limited, PerkinElmer Inc., Eurofins Scientific, F. Hoffmann-La Roche Ltd, NextGen Life Sciences Private Limited, bioMérieux SA, New England Biolabs, Promega Corporation, Merck KGaA, Takara Bio Inc., Abnova Corporation, Thermo Fisher Scientific Inc., Agilent Technologies, Inc., QIAGEN, Bio-Rad Laboratories, Inc., Lonza, CardioNet, ZOLL Medical Corporation and Hill-Rom Services, Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global ribonucleic acid (RNA) markers market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global ribonucleic acid (RNA) markers market

Detailed Segmentation:

• Global Ribonucleic Acid (RNA) Markers Market, By Type:
• Prestained Markers
• Unstained Markers
• Specialty Markers
• Global Ribonucleic Acid (RNA) Markers Market, By Application:
• Nucleic Acid Applications
• Proteomics Applications
• Global Ribonucleic Acid (RNA) Markers Market By End User:
• Research Centers
• Pharmaceutical and Biotechnology Companies
• Others ( Academic Institutes, Forensic Laboratory and Others)
• Global Ribonucleic Acid (RNA) Markers Market, By Region:
• North America
• By Country:
• U.S.
• Canada
• Latin America
• By Country:
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• By Country:
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• By Country
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• By Country:
• GCC
• Israel
• Rest of Middle East
• Africa
• By Country/Region:
• South Africa
• Central Africa
• North Africa
• Company Profiles
• Agilent Technologies, Inc.*
• Company Highlights
• Products Portfolio
• Key Highlights
• Financial Performance
• Strategies
• Oxford Gene Technology IP Limited
• PerkinElmer Inc.
• Eurofins Scientific
• F. Hoffmann-La Roche Ltd
• NextGen Life Sciences Private Limited
• bioMérieux SA
• New England Biolabs
• Promega Corporation
• Merck KGaA
• Takara Bio Inc.
• Abnova Corporation
• Thermo Fisher Scientific Inc.
• QIAGEN
• Bio-Rad Laboratories, Inc.
• Lonza, CardioNet
• ZOLL Medical Corporation
• Hill-Rom Services, Inc.

“*” marked represents similar segmentation in other categories in the respective section.